玻璃体内注射雷珠单抗治疗糖尿病性黄斑水肿的临床效果分析  

Analysis of Clinical Effect of Intravitreal Injection of Ranibizumab in Treatment of Diabetic Macular Edema

作　　者：黄炳护 刘佳凤 杨健 杨晔 梁婷 Huang Binghu;Liu Jiafeng;Yang Jian;Yang Ye;Liang Ting(Ophthalmology Department,The Second Nanning People's Hospital,Nanning 530031,Guangxi Zhuang Autonomous Region,China)

机构地区：[1]南宁市第二人民医院眼科,广西壮族自治区南宁530031

出　　处：《中国社区医师》2025年第5期9-11,共3页Chinese Community Doctors

基　　金：广西壮族自治区卫生健康委员会自筹经费科研项目(编号:Z-A20221145)。

摘　　要：目的:探讨玻璃体内注射雷珠单抗治疗糖尿病性黄斑水肿(DME)的临床效果。方法:选取2021年7月—2022年12月南宁市第二人民医院收治的DME患者60例(患眼60只)进行研究,随机分为观察组(30例,患眼30只)和对照组(30例,患眼30只)。观察组给予玻璃体内注射雷珠单抗治疗,对照组给予玻璃体内注射曲安奈德治疗。比较两组治疗效果。结果:注射后1 d、1周、1个月、3个月,两组视力、最佳矫正视力均高于注射前,且观察组高于对照组(P<0.05)。注射后1 d、1周、1个月、3个月,两组眼压均低于注射前(P<0.05);但两组组间比较,差异无统计学意义(P>0.05)。注射后1 d、1周、3个月,两组中心凹视网膜厚度比注射前薄(P<0.05);但两组组间比较,差异无统计学意义(P>0.05)。注射后1个月,两组中心凹视网膜厚度比注射前薄,且观察组比对照组薄(P<0.05)。注射前后,两组角膜内皮细胞密度比较,差异无统计学意义(P>0.05)。结论:玻璃体内注射雷珠单抗治疗DME的临床效果较好,能够改善患者视力和中心凹视网膜厚度,且安全性较高。Objective:To investigate the clinical effect of intravitreal injection of ranibizumab in the treatment of diabetic macular edema(DME).Methods:A total of 60 patients with DME(60 eyes)admitted to the Second Nanning People's Hospital from July 2021 to December 2022 were selected for study.They were randomly divided into observation group(30 cases,30 eyes)and control group(30 cases,30 eyes).The observation group was treated with intravitreal injection of ranibizumab,and the control group was treated with intravitreal injection of triamcinolone acetonide.The treatment effects were compared between the two groups.Results:On 1 day,1 week,1 month and 3 months after injection,the visual acuity and best corrected visual acuity in the two groups were higher than those before injection,and these parameters in the observation group were higher than those in the control group(P<0.05).At 1 day,1 week,1 month and 3 months after injection,the intraocular pressure in the two groups was lower than that before injection(P<0.05),but there was no statistically significant difference between the two groups(P>0.05).On 1 day,1 week and 3 months after injection,the foveal retinal thickness in the two groups was thinner than that before injection(P<0.05),but there was no statistically significant difference between the two groups(P>0.05).At 1 month after injection,the foveal retinal thickness in the two groups was thinner than that before injection,and this parameter in the observation group was thinner than that in the control group(P<0.05).There was no statistically significant difference in corneal endothelial cell density between the two groups before and after injection(P>0.05).Conclusion:Intravitreal injection of ranibizumab in the treatment of DME has a good clinical effect,and can improve the visual acuity and foveal retinal thickness,and has a high safety.

关 键 词：雷珠单抗 曲安奈德 糖尿病性黄斑水肿 角膜内皮细胞密度 

分 类 号：R587.2[医药卫生—内分泌] R774[医药卫生—内科学]